From monoclonal antibodies to complex recombinant proteins, our integrated mammalian capabilities support biologic programs from early development through clinical manufacturing and toward commercialization.
From recombinant proteins to complex microbial-derived biologics, our integrated bacterial and yeast capabilities support programs from early development through clinical and commercial manufacturing.
From plasmid development to scalable GMP manufacturing, our integrated pDNA capabilities support advanced therapy and biopharmaceutical programs through development, scale-up, and clinical manufacturing.
From vector and process development to cGMP manufacturing, our integrated viral vector capabilities support gene therapy programs from early development through clinical manufacturing.
From process development to cGMP manufacturing, our integrated cell therapy capabilities support complex living-cell products through advanced processing, analytics, and purpose-built manufacturing infrastructure.
ADCs
ADCs service coming in Q2 2027
